Structural glycobiology: Applications in cancer research

Structural Glycobiology

Volumn , Issue , 2012, Pages 177-213

  Brockhausen, Inka ^a   Gao, Yin ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949652859     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12965     Document Type: Chapter

References (195)

1. Amith S. R., Jayanth P., Franchuk S. et al. 2010. Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling. Cell Signal, 22, 314-324.
2. Arnold J. N., Saldova R., Galligan M. C. et al. 2011. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res, 10, 1755-1764.
3. Bachmaier R., Aryee D. N., Jug G. et al. 2009. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing’s sarcoma. Oncogene, 28, 1280-1284.
4. Balagué C., Audié J. P., Porchet N., and Real F. X. 1995. In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology, 109, 953-964.
5. Barash U., Cohen-Kaplan V., Dowek I. et al. 2010. Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS J, 277, 3890-3903.
6. Barthel S. R., Gavino J. D., Wiese G. K. et al. 2008. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology, 18, 806-817.
7. Barthel S. R., Wiese G. K., Cho J. et al. 2009. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci USA, 106, 19491-19496.
8. Bidon-Wagner N. and Le Pennec J. P. 2004. Human galectin-8 isoforms and cancer. Glycoconj J, 19, 557-563.
9. Blottière H. M., Burg C., Zennadi R. et al. 1992. Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity. Int J Cancer, 52, 609-618.
10. Bones J., Byrne J. C., O’Donoghue N. et al. 2011. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res, 10, 1246-1265.
11. Borsig L., Vlodavsky I., Ishai-Michaeli R., Torri G., and Vismara E. 2011. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia, 13, 445-452.
12. Bresalier R. S., Niv Y., Byrd J. C. et al. 1991. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest, 87, 1037-1045.
13. Bresalier R., Ho S., Schoeppner H. et al. 1996. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology, 110, 1354-1367.
14. Brockhausen I., Matta K. L., Orr J., and Schachter H. 1985. Mucin synthesis. UDP-GlcNAc: GalNAc-R beta 3-N-acetylglucosaminyltransferase and UDP-GlcNAc: GlcNAc beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from pig and rat colon mucosa. Biochemistry, 24, 1866-1874.
15. Brockhausen I., Romero P., and Herscovics A. 1991. Glycosyltransferase changes upon differentiation of CaCo-2 human colonic adenocarcinoma cells. Cancer Res, 51, 3136-3142.
16. Brockhausen I., Yang J., Burchell J., Whitehouse C., and Taylor-Papadimitriou J. 1995. Mechanism underlying aberrant glycosylation of the MUC1 mucin in breast cancer cells. Eur J Biochem, 233, 607-617.
17. Brockhausen I. and Kuhns W. 1997. Glycoproteins and human disease, Medical Intelligence Unit. CRC Press and Mosby Year Book. New York: Chapman & Hall.
18. Brockhausen I., Schutzbach J., and Kuhns W. 1998. Glycoproteins and their relationship to human disease. Acta Anat (Basel), 161, 36-78.
19. Brockhausen I., Yang J., Dickinson N., Ogata S., and Itzkowitz S. H. 1998. Enzymatic basis for sialyl-Tn expression in human colon cancer cells. Glycoconj J, 15, 595-603.
20. Brockhausen, I. 1999. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta, 1473, 67-95.
21. Brockhausen I., Yang J., Lehotay M., Ogata S., and Itzkowitz S. H. 2001. Pathways of mucin O-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated Sialyl-Tn antigen expression. Biol Chem, 382, 219-232.
22. Brockhausen I., Benn M., Bhat S. et al. 2006. UDP-Gal: GlcNAc-R β1,4-Galactosyltransferase a target enzyme for drug design. Acceptor specificity and inhibition of the enzyme. Glycoconj J, 23, 525-541.
23. Brockhausen I. 2006. Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep, 7, 599-604.
24. Brockhausen I. 2007. Biochemical aspects: Biosynthesis of mucin-type O-glycans. In Comprehensive Glycosciences (From Chemistry to Systems Biology), Kamerling J. P. (ed). pp. 33-59. Burlington, MA: Acad. Press/Elsevier.
25. Brockhausen I., Dowler T., and Paulsen H. 2009. Site directed processing: Role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2. Biochim Biophys Acta, 1790, 1244-1257.
26. Brockhausen I. 2010. Biosynthesis of complex mucin-type O-glycans. In Comprehensive Natural Products II Chemistry and Biology, Mander L., Lui H. -W., and Wang P. G. (eds). pp. 315-350. Oxford: Elsevier.
27. Brown J. R., Fuster M. M., Li R. et al. 2006. A disaccharide based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clin Cancer Res, 12, 2894-2901.
28. Brown J. R., Yang F., Sinha A. et al. 2009. Deoxygenated disaccharide analogs as specific inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated tumor metastasis. J Biol Chem, 284, 4952-4959.
29. Buckhaults P., Chen L., Fregien N., and Pierce M. 1997. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem, 272, 19575-19581.
30. Burchell J., Poulsom R., Hanby A. et al. 1999. An alpha 2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology, 9, 1307-1311.
31. Burke P. A., Gregg J. P., Bakhtiar B. et al. 2006. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol, 29, 49-55.
32. Caldwell S. A., Jackson S. R., Shahriari K. S. et al. 2010. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene, 29, 2831-2842.
33. Capon C., Maes E., Michalski J. C., Leffler H., and Kim Y.S. 2001. Sd(a)-antigen-like structures carried on core 3 are prominent features of glycans from the mucin of normal human descending colon. Biochem J, 358, 657-664.
34. Casado J. G., Delgado, E., Patsavoudi E. et al. 2008. Functional implications of HNK-1 expression on invasive behaviour of melanoma cells. Tumour Biol, 29, 304-310.
35. Chaturvedi P., Singh A. P., Chakraborty S. et al. 2008. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res, 68, 2065-2070.
36. Chen S. and Fukuda M. 2006. Cell type-specific roles of carbohydrates in tumor metastasis. Methods Enzymol, 416, 371-380.
37. Chen J. Y., Tang Y. A., Huang S.M. et al. 2011. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res, 71, 473-483.
38. Cheung I. Y., Vickers A., and Cheung N. K. 2006. Sialyltransferase STX (ST8SiaII): A novel molecular marker of metastatic neuroblastoma. Int J Cancer, 119, 152-156.
39. Chiang C. H., Wang C. H., Chang H. C. et al. 2010. A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling. J Cell Physiol, 223, 492-499.
40. Chou T. Y., Hart G. W., and Dang C. V. 1995. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem, 270, 18961-18965.
41. Cozzi P. J., Wang J., Delprado W. et al. 2005. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis, 22, 565-573.
42. Dall’Olio F., Malagolini N., di Stefano G. et al. 1989. Increased CMP-NeuAc: Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues. Int J Cancer, 44, 434-439.
43. Dall’Olio F., Chiricolo M., Ceccarelli C. et al. 2000. Beta-galactoside alpha 2,6 sialyltransferase in human colon cancer: Contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin. Int J Cancer, 88, 58-65.
44. Dall’Olio F. and Chiricolo M. 2001. Sialyltransferases in cancer. Glycoconj J, 18, 841-850.
45. Dalziel M., Whitehouse C., McFarlane I. et al. 2001. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem, 276, 11007-11015.
46. De Leoz M. L., An H. J., Kronewitter S. et al. 2008. Glycomic approach for potential biomarkers on prostate cancer: Profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers, 25, 243-258.
47. Delannoy P., Kim I., Emery N. et al. 1996. Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. Glycoconj J, 13, 717-726.
48. Demetriou M., Nabi I. R., Coppolino M., Dedhar S., and Dennis J. W. 1995. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol, 130, 383-392.
49. Dennis J. W., Granovsky M., and Warren C. E. 1999. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta, 1473, 21-34.
50. Devine P. L., Clark B. A., Birrell G. W. et al. 1991. The breast tumor-associated epitope defined by monoclonal antibody 3E1.2 is an O-linked mucin carbohydrate containing N-glycolylneuraminic acid. Cancer Res, 51, 5826-5836.
51. Diamandis E. P. 2010. Cancer biomarkers: Can we turn recent failures into success? J Natl Cancer Inst, 102, 1462-1467.
52. Dohi T., Yuyama Y., Natori Y. et al. 1996. Detection of N-acetylgalactosaminyltransferase mRNA which determines expression of Sda blood group carbohydrate structure in human gastrointestinal mucosa and cancer. Int J Cancer, 67, 626-631.
53. Dohi T. and Kawamura Y. I. 2008. Incomplete synthesis of the Sda/Cad blood group carbohydrate in gastrointestinal cancer. Biochim Biophys Acta, 1780, 467-471.
54. Dwek M. V., Jenks A., and Leathem A. J. 2010. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin Chim Acta, 411, 1935-1939.
55. Fujita T., Murayama K., Hanamura T. et al. 2011. CSLEX (Sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients. Jpn J Clin Oncol, 41, 394-399.
56. Fukushima K., Satoh T., Baba S., and Yamashita K. 2010. (alpha)1,2-fucosylated and (beta)-N-acetylgalactosaminylated prostate specific antigen as an efficient marker of prostatic cancer. Glycobiology, 21, 452-460.
57. Fung P. Y. S., Madej M., Koganty R. R., and Longenecker B. M. 1990. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res, 50, 4308-4314.
58. Fuster M. M., Brown J. R., Wang L., and Esko J. D. 2003. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res, 63, 2775-2781.
59. Gao Y., Lazar C., Szarek W. A., and Brockhausen, I. 2010. Specificity of β4galactosyltransferase inhibitor 2-naphthyl 2-butanamido-2-deoxy-1-thio-beta-D-glucopyranoside. Glycoconj J, 27, 673-684.
60. Gao Y., Chen P. W., Chachadi V., Wang Y., Anastassiades T., and Brockhausen, I. 2010. The Characteristic Glycosylation Potential of Human Prostate Cancer Cells. Glycobiology, 20, 1491. Abstract 131.
61. Garbar C., Mascaux C., and Wespes E. 2008. Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: A preliminary study. Anal Quant Cytol Histol, 30, 71-77.
62. Granovsky M., Fata J., Pawling J. et al. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med, 6, 306-312.
63. Gu Y., Mi W., Ge Y. et al. 2010. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res, 70, 6344-6351.
64. Guo H. B., Zhang Q. S., and Chen H. L. 2000. Effects of H-ras and v-sis overexpression on N-acetylglucosaminyltransferase V and metastasis-related phenotypes in human hepatocarcinoma cells. J Cancer Res Clin Oncol, 126, 263-270.
65. Guo H. B., Johnson H., Randolph M. et al. 2010. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci USA, 107, 21116-21121.
66. Guo Z. and Wang Q. 2009. Recent development in carbohydrate-based cancer vaccines. Curr Opin Chem Biol, 13, 608-617.
67. Hagisawa S., Ohyama C., Takahashi T. et al. 2005. Expression of core 2 beta1, 6-N-acetyl glucosaminyltransferase facilitates prostate cancer progression. Glycobiology, 15, 1016-1024.
68. Hart, G. W., Slawson C., Ramirez-Correa G., and Lagerlof O. 2010. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu Rev Biochem, 80, 825-858.
69. Hatakeyama S., Kyan A., Yamamoto H. et al. 2010. Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int J Cancer, 127, 1052-1059.
70. Hollingsworth M. A. and Swanson B. J. 2004. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60.
71. Hsu C. C., Lin T. W., Chang W. W. et al. 2005. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol, 96, 415-422.
72. Huang M. C., Chen H. Y., Huang H. C. et al. 2006. C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene, 25, 3267-3276.
73. Huang J., Liang J. T., Huang H. C. et al. 2007. Beta1, 4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells. Mol Cancer Res, 5, 543-552.
74. Huang Y. L. and Wu C. Y. 2010. Carbohydrate-based vaccines: Challenges and opportunities. Expert Rev Vaccines, 9, 1257-1274.
75. Idikio H. A. 1997. Sialyl-lewis-X, Gleason grade and stage in non-metastatic human prostate cancer. Glycoconj J, 14, 875-877.
76. Inaba Y., Ohyama C., Kato T. et al. 2003. Gene transfer of alpha1,3-fucosyltransferase increases tumor growth of the PC-3 human prostate cancer cell line through enhanced adhesion to prostatic stromal cells. Int J Cancer, 107, 949-957.
77. Isaji T., Gu J., Nishiuchi R. et al. 2004. Introduction of bisecting GlcNAc into integrin alpha5beta1 reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem, 279, 19747-19754.
78. Ishida H., Togayachi A., Sakai T. et al. 2005. A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett, 579, 71-8.
79. Itano N. and Kimata, K. 2008. Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol, 18, 268-274.
80. Itzkowitz S. H., Bloom E. J., Kokal W. A. et al. 1990. Sialosyl-Tn: A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer, 66, 1960-1966.
81. Iwai T., Kudo T., Kawamoto R. et al. 2005. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci USA, 102, 4572-4577.
82. Jacob G. S. 1995. Glycosylation inhibitors in biology and medicine. Curr Opin Struct Biol, 5, 605-611.
83. Jass J. R. and Walsh M. D. 2001. Altered mucin expression in the gastrointestinal tract: A review. J Cell Mol Med, 5, 327-351.
84. Jiang J. and Gu J. 2010. Beta1,4-galactosyltransferase V A growth regulator in glioma. Methods Enzymol, 479, 3-23.
85. Ju T., Lanneau G. S., Gautam T. et al. 2008. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res, 68, 1636-1646.
86. Julien S., Lagadec C., Krzewinski-Recchi M. et al. 2005. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res Treat, 90, 77-84.
87. Julien S., Adriaenssens E., Ottenberg K. et al. 2006. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology, 16, 54-64.
88. Kariya Y., Kato R., Itoh S. et al. 2008. N-Glycosylation of laminin-332 regulates its biological functions. A novel function of the bisecting GlcNAc. J Biol Chem, 283, 33036-33045.
89. Kim Y. S., Itzkowitz S. H., Yuan M. et al. 1988. Lex and Ley antigen expression in human pancreatic cancer. Cancer Res, 48, 475-482.
90. King M. J., Chan A., Roe R. et al. 1994. Two different glycosyltransferase defects that result in GalNAc alpha-O-peptide (Tn) expression. Glycobiology, 4, 267-279.
91. Kojima N., Handa K., Newman W., and Hakomori S. 1992. Inhibition of selectin-dependent tumor cell adhesion to endothelial cells and platelets by blocking O-glycosylation of these cells. Biochem Biophys Res Commun, 182, 1288-1295.
92. Korja M., Jokilammi A., Salmi T. T. et al. 2009. Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer, 9, 57.
93. Kotera Y., Fontenot J. D., Pecher G., Metzgar R. S., and Finn O. J. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res, 54, 2856-2860.
94. Kovjazin R., Volovitz I., Kundel Y. et al. 2011. ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine, 29, 4676-4686.
95. Kudo T., Ikehara Y., Togayachi A. et al. 1998. Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab Investig, 78, 797-811.
96. Läubli H. and Borsig L. 2010. Selectins promote tumor metastasis. Semin Cancer Biol, 20, 169-177.
97. Lagana A., Goetz J. G., Cheung P. et al. 2006. Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol, 26, 3181-3193.
98. Lau K. S. and Dennis J. W. 2008. N-Glycans in cancer progression. Glycobiology, 18, 750-760.
99. Lee G. and Ge B. 2010. Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol Immunother, 59, 1347-1356.
100. Lee S. H., Hatakeyama S., Yu S. Y. et al. 2009. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J Biol Chem, 284, 17157-17169.
101. Li M., Song L., and Qin X. 2010. Glycan changes: Cancer metastasis and anti-cancer vaccines. J Biosci, 35, 665-673.
102. Li W., Zhang W., Luo J. et al. 2010. Alpha1,3 fucosyltransferase VII plays a role in colorectal carcinoma metastases by promoting the carbohydration of glycoprotein CD24. Oncol Rep, 23, 1609-1617.
103. Li Y. and Cozzi P. J. 2007. MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets, 7, 259-271.
104. Li Y., Yang X., Nguyen A. H., and Brockhausen I. 2007. Requirement of N-glycosylation for the secretion of recombinant extracellular domain of human Fas in HeLa cells. Int J Biochem Cell Biol, 39, 1625-1636.
105. Li Z., Yamada S., Inenaga S. et al. 2011. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer, 104, 1882-1889.
106. Lin Z., Simeone D. M., Anderson M. A. et al. 2011. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res, 10, 2602-2611.
107. Lise M., Belluco C., Perera S. P. et al. 2000. Clinical correlations of alpha 2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma, 19, 281-286.
108. Lloyd K. O., Yin B. W., and Kudryashov V. 1997. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a mucin-type molecule. Int J Cancer, 71, 842-850.
109. Magnani J. L., Steplewski Z., Koprowski H., and Ginsburg V. 1983. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res, 43, 5489-5492.
110. Malykh Y. N., Schauer R., and Shaw L. 2001. N-Glycolylneuraminic acid in human tumours. Biochimie, 83, 623-634.
111. Marcos N. T., Pinho S., Grandela C. et al. 2004. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res, 64, 7050-7057.
112. Martín-Satué M., Marrugat R., Cancelas J. A., and Blanco J. 1998. Enhanced expression of alpha(1,3)-fucosyltransferase genes correlates with E-selectin-mediated adhesion and metastatic potential of human lung adenocarcinoma cells. Cancer Res, 58, 1544-1550.
113. Martín-Satué M., de Castellarnau C., and Blanco J. 1999. Overexpression of alpha(1,3)-fucosyltransferase VII is sufficient for the acquisition of lung colonization phenotype in human lung adenocarcinoma HAL-24Luc cells. Br J Cancer, 80, 1169-1174.
114. Matsuura N., Narita T., Hiraiwa N. et al. 1998. Gene expression of fucosyl-and sialyltransferases which synthesize sialyl Lewis x, the carbohydrate ligands for E-selectin, in human breast cancer. Int J Oncol, 12, 1157-1164.
115. Maupin K. A., Sinha A., Eugster E. et al. 2010. Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS One, 5, e13002.
116. Meany D. L., Zhang Z., Sokoll L. J., Zhang H., and Chan D. W. 2009. Glycoproteomics for prostate cancer detection: Changes in serum PSA glycosylation patterns. J Proteome Res, 8, 613-619.
117. Metzgar R. S., Rodriguez N., Finn O. J. et al. 1984. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci USA, 81, 5242-5246.
118. Mi W., Gu Y., Han C. et al. 2011. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta, 1812, 514-519.
119. Miyoshi E., Shinzaki S., Moriwaki K., and Matsumoto H. 2010. Identification of fucosylated haptoglobin as a novel tumor marker for pancreatic cancer and its possible application for a clinical diagnostic test. Methods Enzymol, 478, 153-164.
120. Miyoshi E., Ito Y., and Miyoshi Y. 2010. Involvement of aberrant glycosylation in thyroid cancer. J Oncol, 2010: 816595.
121. Monzavi-Karbassi B., Stanley J. S., Hennings L. et al. 2007. Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer, 120, 1179-1191.
122. Mungul A., Cooper L., Brockhausen I. et al. 2004. Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice. Internat J Oncol, 25, 937-943.
123. Nakamori S., Kamyama M., Imaoka S. et al. 1993. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study. Cancer Res, 53, 3632-3637.
124. O’Boyle K. P., Zamore R., Adluri S. et al. 1992. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res, 52, 5663-5667.
125. Ogata S., Maimonis P. J., and Itzkowitz S. H. 1992. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res, 52, 4741-4746.
126. Ogawa J. I., Inoue H., and Koide S. 1997. Alpha-2, 3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma. Cancer, 79, 1678-1685.
127. Ohyama C., Hosono M., Nitta. K. et al. 2004. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology, 14, 671-679.
128. Ohyama C. 2008. Glycosylation in bladder cancer. Int J Clin Oncol, 13, 308-313.
129. Orntoft T. F., Harving N., and Langkilde N. C. 1990. O-Linked mucin-type glycoproteins in normal and malignant colon mucosa: Lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas. Int J Cancer, 45, 666-672.
130. Osunkoya A. O., Adsay N. V., Cohen C., Epstein J. I., and Smith S. L. 2008. MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: An analysis of 50 cases on radical prostatectomy. Mod Pathol, 21, 789-794.
131. Park J. H., Nishidate T., Kijima K. et al. 2010. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res, 70, 2759-2769.
132. Park J. H., Katagiri T., Chung S., Kijima K., and Nakamura Y. 2011. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia, 13, 320-326.
133. Patsos G., Hebbe-Viton V., Robbe-Masselot C. et al. 2009. O-Glycan inhibitors generate aryl-glycans, induce apoptosis and lead to growth inhibition in colorectal cancer cell lines. Glycobiology, 19, 382-398.
134. Peracaula R., Tabarés G., Royle L. et al. 2003. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-470.
135. Peracaula R., Barrabés S., Sarrats A., Rudd P. M., and de Llorens R. 2008. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers, 25, 207-218.
136. Pérez-Garay M., Arteta B., Pagès L. et al. 2010. Alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS One, 5, e12524.
137. Petretti T., Kemmner W., Schulze B., and Schlag P. M. 2000. Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut, 46, 359-366.
138. Picco G., Julien S., Brockhausen I. et al. 2010. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology, 20, 1241-1250.
139. Pinho S., Marcos N. T., Ferreira B. et al. 2007. Biological significance of cancer-associated sialyl-Tn antigen: Modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett, 249, 157-170.
140. Pinho S. S., Osório H., Nita-Lazar M. et al. 2009. Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem Biophys Res Commun, 379, 1091-1096.
141. Premaratne P., Welén K., Damber J. E., Hansson G. C., and Backstrom M. 2011. O-Glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model. Tumour Biol, 32, 203-213.
142. Przybylo M. and Lityńska A. 2011. Glycans in melanoma screening. Part 1. The role of β1,6-branched N-linked oligosaccharides in melanoma. BiochemSoc Trans, 39, 370-373.
143. Rajpert-De Meyts E., Poll S. N., Goukasian I. et al. 2007. Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch, 451, 805-814.
144. Saito H., Gu J., Nishikawa A. et al. 1995. Organization of the human N-acetylglucosaminyltransferase V gene. Eur J Biochem, 233, 18-26.
145. Sarrats A., Saldova R., Comet J. et al. 2010. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. OMICS, 14, 465-474.
146. Sawada T., Ho J. J., Chung Y. S., Sowa M., and Kim Y. S. 1994. E-selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int J Cancer, 57, 901-907.
147. Sayat R., Leber B., Grubac V., Wiltshire L., and Persad S. 2008. O-GlcNAc-glycosylation of beta-catenin regulates its nuclear localization and transcriptional activity. Exp Cell Res, 314, 2774-2787.
148. Schneider F., Kemmer W., Haensch W. et al. 2001. Overexpression of sialyltransferase CMP-sialic acid: Galbeta1,3GalNAc-R alpha6-sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res, 61, 4605-4611.
149. Seko A. and Yamashita K. 2005. Characterization of a novel galactose beta1, 3-N-acetylglucosaminyltransferase (beta3Gn-T8): The complex formation of beta3Gn-T2 and beta3Gn-T8 enhances enzymatic activity. Glycobiology, 15, 943-951.
150. Sewell R., Baeckstroem M., Dalziel M. et al. 2006. The ST6GalNAc-I sialyltransferase localises throughout the Golgi and is responsible for the synthesis of the tumour-associated sialyl Tn O-glycan in human breast cancer. J Biol Chem, 281, 3586-3594.
151. Shen Y., Kohla G., Lrhorfi A. L. et al. 2004. O-Acetylation and de-O-acetylation of sialic acids in human colorectal carcinoma. Eur J Biochem, 271, 281-290.
152. Shibao K., Izumi H., Nakayama Y. et al. 2002. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectoral carcinoma. Cancer, 94, 1939-1946.
153. Shimodaira K., Nakayama J., Nakamura N. et al. 1997. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: Role of O-glycans in tumor progression. Cancer Res, 57, 5201-5206.
154. Simpson M. A. and Lokeshwar V. B. 2008. Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci, 13, 5664-5680.
155. Slawson C., Copeland R. J., and Hart G. W. 2010. O-GlcNAc signaling: A metabolic link between diabetes and cancer? Trends Biochem Sci, 35, 547-555.
156. Song Y., Aglipay J. A., Bernstein J. D., Goswami S., and Stanley P. 2010. The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res, 70, 3361-3371.
157. Springer G. F., Desai P. R., Spencer B. D. et al. 1995. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Cancer Detect Prev, 19, 374-380.
158. Springer G. F. 1997. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med, 75, 594-602.
159. Srinivasan N., Bane S. M., Ahire S. D., Ingle A. D., and Kalraiya R.D. 2009. Poly N-acetyllactosamine substitutions on N-and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J, 26, 445-456.
160. Stannard K. A., Collins P. M., Ito K. et al. 2010. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett, 299, 95-110.
161. St. Hill C. A., Farooqui M., Mitcheltree G. et al. 2009. The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1, 6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer, 9, 79.
162. Sun J. Y., Zhu M. Z., Wang S. W. et al. 2007. Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine, 14, 353-359.
163. Suriano R., Ghosh S. K., Ashok B. T. et al. 2005. Differences in glycosylation patterns of heat shock protein, gp96: Implications for prostate cancer prevention. Cancer Res, 65, 6466-6475.
164. Suriano R., Ghosh S. K., Chaudhuri D. et al. 2009. Sialic acid content of tissue-specific gp96 and its potential role in modulating gp96-macrophage interactions. Glycobiology, 19, 1427-1435.
165. Swindall A. F. and Bellis S. L. 2011. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem, 286, 22982-22990.
166. Tabarés G., Radcliffe C.M., Barrabés S. et al. 2006. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology, 16, 132-145.
167. Tabarés G., Jung K., Reiche J. et al. 2007. Free PSA forms in prostatic tissue and sera of prostate cancer patients: Analysis by 2-DE and western blotting of immunopurified samples. Clin Biochem, 40, 343-350.
168. Tajiri M., Ohyama C., and Wada Y. 2008. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: A glycopeptide approach. Glycobiology, 18, 2-8.
169. Takenaka Y., Fukumori T., and Raz A. 2004. Galectin-3 and metastasis. Glycoconj J, 19, 543-549.
170. Tanaka F., Otake Y., Nakagawa T. et al. 2000. Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. Cancer Res, 60, 3072-3080.
171. Taniuchi K., Cerny R. L., Tanouchi A. et al. 2011. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene, 30, 4843-4854.
172. Tarp M. A. and Clausen H. 2008. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta, 1780, 546-563.
173. Toscano M. A., Bianco G. A., Ilarregui J. M. et al. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol, 8, 825-834.
174. Trinchera M., Malagolini N., Chiricolo M. et al. 2011. The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. Int J Biochem Cell Biol, 43, 130-139.
175. Tsui K. H., Chang P. L., Feng T. H. et al. 2008. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Res, 28, 1993-1999.
176. Valentiner U., Mühlenhoff M., Lehmann U., Hildebrandt H., and Schumacher U. 2011. Expression of the neural cell adhesion molecule and polysialic acid in human neuroblastoma cell lines. Int J Oncol, 39, 417-424.
177. Valenzuela H. F., Pace K. E., Cabrera P. V. et al. 2007. O-Glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res, 67, 6155-6162.
178. Vavasseur F., Dole K., Yang J. et al. 1994. O-Glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur J Biochem, 222, 415-424.
179. Vavasseur F., Yang J., Dole K., Paulsen H., and Brockhausen I. 1995. Synthesis of O-glycan core 3: Characterization of UDP-GlcNAc: GalNAc-R beta3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines. Glycobiology, 5, 351-357.
180. Vlodavsky I., Korner G., Ishai-Michaeli R. et al. 1990. Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev, 9, 203-226.
181. Wang F. L., Cui S. X., Sun L. P. et al. 2009. High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer. Cancer Detect Prev, 32, 437-443.
182. Wang Q., Zhang J., and Guo Z. 2007. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cells. Bioorg Med Chem, 15, 7561-7567.
183. Ween M. P., Hummitzsch K., Rodgers R. J., Oehler M. K., and Ricciardelli C. 2011. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis, 28, 113-125.
184. Wu C., Guo X., Wang W. et al. 2010. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer, 10, 123.
185. Yamori T., Kimura H., Stewart K. et al. 1987. Differential production of high molecular weight sulfated glycoproteins in normal colonic mucosa, primary colon carcinoma, and metastases. Cancer Res, 47, 2741-2747.
186. Yang J. M., Byrd J. C., Siddiki B. B. et al. 1994. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology, 4, 873-884.
187. Yang W. H., Kim J. E., Nam H. W. et al. 2006. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol, 8, 1074-1083.
188. Yang X., Yip J., Harrison M., and Brockhausen I. 2008. Primary human osteoblasts and bone cancer cells as models to study glycodynamics in bone. Internat J Biochem Cell Biol, 40, 471-483.
189. Yoon S. J., Park S. Y., Pang P. C. et al. 2010. N-Glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. Int J Oncol, 36, 193-203.
190. Yoshimura M., Nishikawa A., Ihara Y., Taniguchi S., and Taniguchi N. 1995. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci USA, 92, 8754-8758.
191. Yu L. G., Andrews N., Zhao Q. et al. 2007. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem, 282, 773-781.
192. Zhang J., Nakayama J., Ohyama C. et al. 2002. Sialyl Lewis X-dependent lung colonization of B16 melanoma cells through a selectin-like endothelial receptor distinct from E-or P-selectin. Cancer Res, 62, 4194-4198.
193. Zhao Y. Y., Takahashi M., Gu J. G. et al. 2008. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci, 99, 1304-1310.
194. Zhou X., Chen H., Wang Q., Zhang L., and Zhao J. 2011. Knockdown of Mgat5 inhibits CD133+ human pulmonary adenocarcinoma cell growth in vitro and in vivo. Clin Invest Med, 34, E155.
195. Zhu Y., Srivatana U., Ullah A. et al. 2001. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta, 1536, 148-160.